FindMyKOL

Alan Parsa, MD

Basic profile

University of Hawaiʻi at Mānoa

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionHonolulu, HI · WestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: NationalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Alan Parsa is an Endocrinology/Metabolic physician affiliated with University of Hawaiʻi at Mānoa. OpenAlex indexes 64 publications with 2,050 citations (h-index 20).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
64publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

2,050citations

Citations across these publications.

20h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
30companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Eli Lilly
    Program year202512 paymentsResearch
    $892,738
  • AbbVie
    Program year202510 paymentsResearch
    $134,422
  • Corcept Therapeutics
    Program year202555 payments
    $74,692
All 89 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    69.3%
    GLP-1 receptor agonist22.6%
    Ozempic51%Trulicity31%Rybelsus9%Mounjaro5%Victoza 3-Pak5%
    Part D<11 patients
    Insulin Analog15.8%
    Lantus Solostar25%Tresiba Flextouch U-10020%Novolog Flexpen19%Humalog Kwikpen U-10016%Toujeo Max Solostar9%Basaglar Kwikpen U-1008%Tresiba Flextouch U-2005%
    Part D<11 patients

    + 9 more classes in this area

  • Hormonal (systemic)

    17.3%
    l-Thyroxine11.6%
    Levothyroxine Sodium90%Synthroid10%
    Part D≥109 patients
    Thyroid Hormone Synthesis Inhibitor2.9%
    Methimazole100%
    Part D≥37 patients

    + 3 more classes in this area

  • Cardiovascular

    6.2%
    Statin1.9%
    Atorvastatin Calcium55%Simvastatin25%Rosuvastatin Calcium20%
    Part D<11 patients
    Nonsteroidal Mineralocorticoid-Receptor Antagonist1.7%
    Kerendia100%
    Part D≥13 patients

    + 4 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

All 50 publications: search, sort and filter.Explore →

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”